NASDAQ : PRME
Prime Medicine, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 5.24 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 932.22M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 839.71M |
| Enterprise Value | 857.12M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 177.90M |
| Shares Outstanding | 177.90M |
| Shares Change (YoY) | +36.42% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 14.52% |
| Owned by Institutions (%) | 54.07% |
| Float | 112.25M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 206.16 |
| Forward PS | 86.24 |
| PB Ratio | 21.02 |
| P/TBV Ratio | 21.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 210.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.05 |
| Quick Ratio | 3.00 |
| Debt / Equity | 2.83 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -373.29% |
| Return on Assets (ROA) | -46.52% |
| Return on Invested Capital (ROIC) | -73.79% |
| Return on Capital Employed (ROCE) | -90.42% |
| Weighted Average Cost of Capital (WACC) | 15.28% |
| Revenue Per Employee | $27,897 |
| Profits Per Employee | -$1.29M |
| Employee Count | 146 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.38 |
| 52-Week Price Change | +3.97% |
| 50-Day Moving Average | 3.54 |
| 200-Day Moving Average | 3.49 |
| Relative Strength Index (RSI) | 61.54 |
| Average Volume (20 Days) | 6,446,401 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 32.87M |
| Short Previous Month | 32.12M |
| Short % of Shares Out | 18.48% |
| Short % of Float | 29.28% |
| Short Ratio (days to cover) | 6.80 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.07M |
| Gross Profit | -142.13M |
| Operating Income | -196.52M |
| Pretax Income | -187.89M |
| Net Income | -187.89M |
| EBITDA | -189.12M |
| EBIT | -196.52M |
| Loss Per Share | -$1.09 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 95.07M |
| Total Debt | 112.48M |
| Net Cash | -17.41M |
| Net Cash Per Share | -$0.10 |
| Equity (Book Value) | 39.81M |
| Book Value Per Share | 0.22 |
| Working Capital | 65.11M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -156.05M |
| Capital Expenditures | -797,000 |
| Depreciation & Amortization | 7.40M |
| Net Borrowing | n/a |
| Free Cash Flow | -156.85M |
| FCF Per Share | -$0.88 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -4,824.94% |
| Pretax Margin | -4,613.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -36.42% |
| Shareholder Yield | -36.42% |
| Earnings Yield | -22.99% |
| FCF Yield | -18.68% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.30 |
| Price Target Difference | 54.56% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 51.23% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.87 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |